301258 Stock Overview
Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the manufacture and sale of biopharmaceutical products in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Suzhou Fushilai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥40.52 |
| 52 Week High | CN¥45.00 |
| 52 Week Low | CN¥19.66 |
| Beta | 0.46 |
| 1 Month Change | 43.18% |
| 3 Month Change | 90.95% |
| 1 Year Change | 3.84% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -39.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301258 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 44.0% | 4.0% | 1.3% |
| 1Y | 3.8% | -8.1% | -11.5% |
Return vs Industry: 301258 exceeded the CN Pharmaceuticals industry which returned -8.1% over the past year.
Return vs Market: 301258 exceeded the CN Market which returned -11.5% over the past year.
Price Volatility
| 301258 volatility | |
|---|---|
| 301258 Average Weekly Movement | 12.7% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 11.8% |
| 10% least volatile stocks in CN Market | 4.6% |
Stable Share Price: 301258's share price has been volatile over the past 3 months.
Volatility Over Time: 301258's weekly volatility has increased from 8% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 544 | Xiangyun Qian | www.fuslai.com |
Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the manufacture and sale of biopharmaceutical products in China. It primarily focuses on manufacturing Alpha Lipoic Acid, L-Carnosine, and Phosphatidylcholine series of products. Its products are primarily used in medicines, dietary supplements, cosmetics, and other fields.
Suzhou Fushilai Pharmaceutical Co., Ltd. Fundamentals Summary
| 301258 fundamental statistics | |
|---|---|
| Market cap | CN¥3.10b |
| Earnings (TTM) | CN¥66.36m |
| Revenue (TTM) | CN¥429.09m |
56.0x
P/E Ratio8.7x
P/S RatioIs 301258 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301258 income statement (TTM) | |
|---|---|
| Revenue | CN¥429.09m |
| Cost of Revenue | CN¥291.21m |
| Gross Profit | CN¥137.88m |
| Other Expenses | CN¥71.52m |
| Earnings | CN¥66.36m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 32.13% |
| Net Profit Margin | 15.47% |
| Debt/Equity Ratio | 0% |
How did 301258 perform over the long term?
See historical performance and comparison